Pub Date : 2020-01-15DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.01.009
Dingjie Li, Ru Liu, Chengliang Yang, Jinhu Chen, Tai An, H. Ge
Objective To compare relevant dosimetric parameters of non-coplanar volumetric modulated arc therapy (VMAT) in treating brain tumors in conventional flattening filter (FF) or flattening filter-free (FFF) delivery mode, aiming to explore the appropriate evaluation method of accelerator for stereotactic radiosurgery (SRS). Methods Clinical data of 10 patients with single cranial tumor were retrospectively analyzed. All patients received non-coplanar VMAT at a prescription dose of 25 Gy in 1 fraction. Dosimetric parameters including conformity index (CI), heterogeneity index (HI), gradient index (GI50, GI25), gradient, volume of the brain tissue receiving larger than 10 Gy and 12 Gy(V10 and V12) and beam-on time were statistically compared between two treatment plans by paired sample t-test. Results When FFF-VMAT was compared with FF-VMAT in SRS for intracranial tumors, Paddick gradient index GI50 was 2.91±0.34 vs.3.07±0.35, 6.91±0.28 vs.7.35±0.27 for GI25, (0.57±0.07) cm vs.(0.61±0.08) cm for gradient, respectively (all P 0.05). For the normal brain tissues, the average dose was (160.64±43.64) cGy vs.(174.27±53.98) cGy, (45.35±30.32)% vs.(48.37±30.88)% for V10 and (36.69±25.15)% vs.(39.48±25.37)% for V12, respectively (all P<0.05). Conclusions Non-coplanar VMAT in FFF delivery mode can improve dose distribution and normal brain tissue sparing in the treatment of intracranial single tumors. Meanwhile, supplement of GI index and gradient index can implement comprehensive evaluation of the SRS planning. Key words: Brain neoplasm/stereotactic radiosurgery; Flattening filter-free beam; Dosimetry
{"title":"Dosimetric comparison between non-coplanar volumetric modulated arc therapy using flattening filter and flattening filter-free beams during stereotactic radiosurgery for brain tumors","authors":"Dingjie Li, Ru Liu, Chengliang Yang, Jinhu Chen, Tai An, H. Ge","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.01.009","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.01.009","url":null,"abstract":"Objective \u0000To compare relevant dosimetric parameters of non-coplanar volumetric modulated arc therapy (VMAT) in treating brain tumors in conventional flattening filter (FF) or flattening filter-free (FFF) delivery mode, aiming to explore the appropriate evaluation method of accelerator for stereotactic radiosurgery (SRS). \u0000 \u0000 \u0000Methods \u0000Clinical data of 10 patients with single cranial tumor were retrospectively analyzed. All patients received non-coplanar VMAT at a prescription dose of 25 Gy in 1 fraction. Dosimetric parameters including conformity index (CI), heterogeneity index (HI), gradient index (GI50, GI25), gradient, volume of the brain tissue receiving larger than 10 Gy and 12 Gy(V10 and V12) and beam-on time were statistically compared between two treatment plans by paired sample t-test. \u0000 \u0000 \u0000Results \u0000When FFF-VMAT was compared with FF-VMAT in SRS for intracranial tumors, Paddick gradient index GI50 was 2.91±0.34 vs.3.07±0.35, 6.91±0.28 vs.7.35±0.27 for GI25, (0.57±0.07) cm vs.(0.61±0.08) cm for gradient, respectively (all P 0.05). For the normal brain tissues, the average dose was (160.64±43.64) cGy vs.(174.27±53.98) cGy, (45.35±30.32)% vs.(48.37±30.88)% for V10 and (36.69±25.15)% vs.(39.48±25.37)% for V12, respectively (all P<0.05). \u0000 \u0000 \u0000Conclusions \u0000Non-coplanar VMAT in FFF delivery mode can improve dose distribution and normal brain tissue sparing in the treatment of intracranial single tumors. Meanwhile, supplement of GI index and gradient index can implement comprehensive evaluation of the SRS planning. \u0000 \u0000 \u0000Key words: \u0000Brain neoplasm/stereotactic radiosurgery; Flattening filter-free beam; Dosimetry","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"39-42"},"PeriodicalIF":0.0,"publicationDate":"2020-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42823769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-15DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.01.014
Xin Sun, Y. Men, Z. Hui
ⅢA-N2 NSCLC is a group of heterogeneous diseases. The optimal treatment modality remains controversial. How to choose suitable neoadjuvant treatment modalities including chemotherapy, radiotherapy, target therapy and immunotherapy remains unclear. In this article, research progress on neoadjuvant therapy of NSCLC was reviewed to evaluate the efficacy and safety for different modalities. Key words: Carcinoma, non-small cell lung/neoadjuvant therapy; Research progress
{"title":"Research progress onneoadjuvant therapy in stage IIIA-N2 non-small cell lung cancer","authors":"Xin Sun, Y. Men, Z. Hui","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.01.014","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.01.014","url":null,"abstract":"ⅢA-N2 NSCLC is a group of heterogeneous diseases. The optimal treatment modality remains controversial. How to choose suitable neoadjuvant treatment modalities including chemotherapy, radiotherapy, target therapy and immunotherapy remains unclear. In this article, research progress on neoadjuvant therapy of NSCLC was reviewed to evaluate the efficacy and safety for different modalities. \u0000 \u0000 \u0000Key words: \u0000Carcinoma, non-small cell lung/neoadjuvant therapy; Research progress","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"61-64"},"PeriodicalIF":0.0,"publicationDate":"2020-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46125218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-15DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.01.008
Guanlin Lu, Shilin Fang, Yanan Peng, Qiu-ya Zhao, Xianyan Shi
Objective To preliminarily evaluate the clinical efficacy of endoscopic argon plasma coagulation (APC) combined with sub-mucosal injection of norepinephrine saline in the treatment of radiation proctitis (RP), especially for refractory RP. Methods Clinical data of 22 RP patients were retrospectively analyzed. The severity of RP was evaluated by a modified endoscopy scoring system (A) or Sherman′s classification (B). The criteria of successful treatment are the improvement of clinical symptoms or the cessation of bleeding (or only occasional traces of blood on the stools that do not need further treatment). Results All 22 patients were successfully treated. Among them, 18 patients (82%) had no bleeding. According to the classification of A, 15 patients (68%) had mild proctitis and 7(32%) experienced severe proctitis. Based on B classification, 9 patients (41%) were categorized as mild proctitis and 13(59%) as severe proctitis. Using the classification of A, the number of treatment sessions was significantly correlated with the endoscopic grade (or endoscopic total score)(Spearman’s r=0.86, P<0.001). Conclusions Preliminary evidence demonstrates that endoscopic APC combined with sub-mucosal injection of norepinephrine saline is not only effective for mild and moderate RP, but also maintains long-term efficacy for refractory RP. Modified endoscopy scoring system (A) assessment is more suitable for clinical application compared with B assessment. Key words: Radiation proctitis/argon plasma coagulation; Radiation proctitis/combined therapy; Treatment outcome
{"title":"Preliminary clinical analysis of radiation proctitis treated with argon plasma coagulation combined with submucosal injection","authors":"Guanlin Lu, Shilin Fang, Yanan Peng, Qiu-ya Zhao, Xianyan Shi","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.01.008","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.01.008","url":null,"abstract":"Objective \u0000To preliminarily evaluate the clinical efficacy of endoscopic argon plasma coagulation (APC) combined with sub-mucosal injection of norepinephrine saline in the treatment of radiation proctitis (RP), especially for refractory RP. \u0000 \u0000 \u0000Methods \u0000Clinical data of 22 RP patients were retrospectively analyzed. The severity of RP was evaluated by a modified endoscopy scoring system (A) or Sherman′s classification (B). The criteria of successful treatment are the improvement of clinical symptoms or the cessation of bleeding (or only occasional traces of blood on the stools that do not need further treatment). \u0000 \u0000 \u0000Results \u0000All 22 patients were successfully treated. Among them, 18 patients (82%) had no bleeding. According to the classification of A, 15 patients (68%) had mild proctitis and 7(32%) experienced severe proctitis. Based on B classification, 9 patients (41%) were categorized as mild proctitis and 13(59%) as severe proctitis. Using the classification of A, the number of treatment sessions was significantly correlated with the endoscopic grade (or endoscopic total score)(Spearman’s r=0.86, P<0.001). \u0000 \u0000 \u0000Conclusions \u0000Preliminary evidence demonstrates that endoscopic APC combined with sub-mucosal injection of norepinephrine saline is not only effective for mild and moderate RP, but also maintains long-term efficacy for refractory RP. Modified endoscopy scoring system (A) assessment is more suitable for clinical application compared with B assessment. \u0000 \u0000 \u0000Key words: \u0000Radiation proctitis/argon plasma coagulation; Radiation proctitis/combined therapy; Treatment outcome","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"35-38"},"PeriodicalIF":0.0,"publicationDate":"2020-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42551728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-15DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.1.012
Xueyuan Li, Qiankun Liu, Shanpeng Yuan, Y. Zhen, Lixin Wu, Wenzheng Luo, Kang Wang, Zhuang Wang, P. Gao, T. Liang, Dongming Yan
Objective To investigate the effect of lncRNA GIHCG on the radiosensitivity of glioma cells and its mechanism. Methods The expression levels of GIHCG and miR-146a-3p in human brain normal glial cells HEB and glioma cell lines U251, A172, SHG139 and U87 were quantitatively measured by qRT-PCR assay. U251 and SHG139 cells were used for subsequent experiment. After silencing the expression of GIHCG or overexpressing miR-146a-3p in U251 and SHG139 cells, cell proliferation was detected by MTT assay, cell apoptosis was detected by flow cytometry, cell radiosensitivity was detected by colony formation assay and the expression levels of CDK1, CyclinD1, Bcl-2 and Bax proteins were measured by Western blot. The bioinformatics software predicted the presence of a binding site for GIHCG and miR-146a-3p. Dual luciferase reporter gene assay and qRT-PCR assay were adopted to verify the targeting relationship between GIHCG and miR-146a-3p. Results Compared with HEB cells, the expression of GIHCG was significantly up-regulated in glioma U87, U251, A172 and SHG139 cells (all P<0.05), whereas that of miR-146a-3p was remarkably down-regulated (P<0.05). Silencing GIHCG expression or overexpression of miR-146a-3p significantly decreased the U251 and SHG139 cell survival rate, survival fraction and the expression of CDK1, CyclinD1 and Bcl-2 proteins (all P<0.05), whereas considerably increased the apoptotic rate and expression of Bax protein (both P<0.05). GIHCG performed targeted negative regulation of miR-146a-3p expression in U251 and SHG139 cells and inhibition of miR-146a-3p expression reversed the effect of silencing GIHCG on proliferation, apoptosis and radiosensitivity of glioma cells. Conclusion Silencing GIHCG expression up-regulates the expression of miR-146a-3p, thereby enhancing the radiosensitivity of glioma cells. Key words: Glioma; lncRNA GIHCG; miR-146a-3p gene; Radiosensitivity
{"title":"Silencing lncRNA GIHCG increases radiosensitivity of glioma cells by up-regulating miR-146a-3p","authors":"Xueyuan Li, Qiankun Liu, Shanpeng Yuan, Y. Zhen, Lixin Wu, Wenzheng Luo, Kang Wang, Zhuang Wang, P. Gao, T. Liang, Dongming Yan","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.1.012","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.1.012","url":null,"abstract":"Objective \u0000To investigate the effect of lncRNA GIHCG on the radiosensitivity of glioma cells and its mechanism. \u0000 \u0000 \u0000Methods \u0000The expression levels of GIHCG and miR-146a-3p in human brain normal glial cells HEB and glioma cell lines U251, A172, SHG139 and U87 were quantitatively measured by qRT-PCR assay. U251 and SHG139 cells were used for subsequent experiment. After silencing the expression of GIHCG or overexpressing miR-146a-3p in U251 and SHG139 cells, cell proliferation was detected by MTT assay, cell apoptosis was detected by flow cytometry, cell radiosensitivity was detected by colony formation assay and the expression levels of CDK1, CyclinD1, Bcl-2 and Bax proteins were measured by Western blot. The bioinformatics software predicted the presence of a binding site for GIHCG and miR-146a-3p. Dual luciferase reporter gene assay and qRT-PCR assay were adopted to verify the targeting relationship between GIHCG and miR-146a-3p. \u0000 \u0000 \u0000Results \u0000Compared with HEB cells, the expression of GIHCG was significantly up-regulated in glioma U87, U251, A172 and SHG139 cells (all P<0.05), whereas that of miR-146a-3p was remarkably down-regulated (P<0.05). Silencing GIHCG expression or overexpression of miR-146a-3p significantly decreased the U251 and SHG139 cell survival rate, survival fraction and the expression of CDK1, CyclinD1 and Bcl-2 proteins (all P<0.05), whereas considerably increased the apoptotic rate and expression of Bax protein (both P<0.05). GIHCG performed targeted negative regulation of miR-146a-3p expression in U251 and SHG139 cells and inhibition of miR-146a-3p expression reversed the effect of silencing GIHCG on proliferation, apoptosis and radiosensitivity of glioma cells. \u0000 \u0000 \u0000Conclusion \u0000Silencing GIHCG expression up-regulates the expression of miR-146a-3p, thereby enhancing the radiosensitivity of glioma cells. \u0000 \u0000 \u0000Key words: \u0000Glioma; lncRNA GIHCG; miR-146a-3p gene; Radiosensitivity","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"52-56"},"PeriodicalIF":0.0,"publicationDate":"2020-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48299882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-15DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.01.011
Yang He, Jinyan Lei, H. Peng, Huanli Luo, K. Mao, Dengyan Wang, Lifeng Peng, Yiyu Zhu, Qinghong Min, Xuechun Wang, Huan Tang, Qian Xiao, Ying Wang
Objective To investigate the correlation between skin elasticity and setup error in optical surface image-guided radiotherapy. Methods The skin elasticity (R7) data of the head, chest and abdomen were extracted and analyzed its correlation with age by systematic literature review. Fifty-four patients diagnosed with nasopharyngeal carcinoma, breast cancer and cervical cancer were recruited in this study. Firstly, the patients were positioned based on the room laser and markers. Subsequently, the patient position was verified by the Varian On-Board Imager, and then C-Rad Catalyst was adopted to obtain surface images in two states (mask or non-mask) as reference images. In the subsequent fraction treatment, after initial positioning, the local calibration was performed by Catalyst, and setup errors in three directions were recorded. Meanwhile, the patient setup was verified by CBCT twice a week. The Pearson correlation analysis was performed to analyze the correlation between setup error and age. Results The skin elasticity was negatively correlated with aging (P SI>AP. Conclusion In optical surface-guided radiotherapy of head and neck cancer, skin elasticity may be a significant index for assessing the setup errors in male patients. Key words: Skin elasticity; Surface image-guided radiotherapy; Set-up error
{"title":"The effect of age on skin elasticity and setup error in optical surface image-guided radiotherapy","authors":"Yang He, Jinyan Lei, H. Peng, Huanli Luo, K. Mao, Dengyan Wang, Lifeng Peng, Yiyu Zhu, Qinghong Min, Xuechun Wang, Huan Tang, Qian Xiao, Ying Wang","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.01.011","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.01.011","url":null,"abstract":"Objective \u0000To investigate the correlation between skin elasticity and setup error in optical surface image-guided radiotherapy. \u0000 \u0000 \u0000Methods \u0000The skin elasticity (R7) data of the head, chest and abdomen were extracted and analyzed its correlation with age by systematic literature review. Fifty-four patients diagnosed with nasopharyngeal carcinoma, breast cancer and cervical cancer were recruited in this study. Firstly, the patients were positioned based on the room laser and markers. Subsequently, the patient position was verified by the Varian On-Board Imager, and then C-Rad Catalyst was adopted to obtain surface images in two states (mask or non-mask) as reference images. In the subsequent fraction treatment, after initial positioning, the local calibration was performed by Catalyst, and setup errors in three directions were recorded. Meanwhile, the patient setup was verified by CBCT twice a week. The Pearson correlation analysis was performed to analyze the correlation between setup error and age. \u0000 \u0000 \u0000Results \u0000The skin elasticity was negatively correlated with aging (P SI>AP. \u0000 \u0000 \u0000Conclusion \u0000In optical surface-guided radiotherapy of head and neck cancer, skin elasticity may be a significant index for assessing the setup errors in male patients. \u0000 \u0000 \u0000Key words: \u0000Skin elasticity; Surface image-guided radiotherapy; Set-up error","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"47-51"},"PeriodicalIF":0.0,"publicationDate":"2020-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48924403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-15DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.01.004
W. Shen, Hong-mei Gao, Shuchai Zhu, Y. Cao, Shu-guang Li, Jinrui Xu
Objective To evaluate the effect of different irradiation methods on the long-term prognosis of patients with clinical T2-3N0M0 esophageal squamous cell carcinoma, aiming to select the optimal treatment for these patients. Methods A total of 268 eligible patients admitted to our hospital from January 2007 to December 2012 were enrolled in this study. All patients were divided into the involved-field irradiation (IFI) and elective node irradiation (ENI) groups. The composition ratio, prognostic factors and adverse events were analyzed between two groups. Results The median overall survival (OS) time was 35.5 months (95%CI : 30.12-40.88) and the median disease-free survival (DFS) time was 23.5 months (95%CI: 19.00-28.00). According to the multivariate analysis results, all patients were assigned into two groups at a ratio of 1 vs.1(n=86 in each group). Multivariate analysis after propensity score matching (PSM) demonstrated that irradiation method was the independent factor of OS (P=0.038), and T stage and radiotherapy were the independent factors affecting DFS (P=0.002, 0.032). The incidence of ≥grade Ⅱ adverse events did not significantly differ between two groups (P=0.819, 0.756). However, patients with combined chemotherapy experienced more adverse events. Conclusion ENI can prolong the OS and DFS of patients with clinical T2-3N0M0 esophageal squamous cell carcinoma, and does not increase the incidence of severe adverse events. Key words: Esophageal neoplasm/involved-field irradiation; Esophageal neoplasm/elective node irradiation; Prognosis
{"title":"Prognosis of different irradiation methods in patients with T2-3N0M0 esophageal squamous cell carcinoma","authors":"W. Shen, Hong-mei Gao, Shuchai Zhu, Y. Cao, Shu-guang Li, Jinrui Xu","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.01.004","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.01.004","url":null,"abstract":"Objective \u0000To evaluate the effect of different irradiation methods on the long-term prognosis of patients with clinical T2-3N0M0 esophageal squamous cell carcinoma, aiming to select the optimal treatment for these patients. \u0000 \u0000 \u0000Methods \u0000A total of 268 eligible patients admitted to our hospital from January 2007 to December 2012 were enrolled in this study. All patients were divided into the involved-field irradiation (IFI) and elective node irradiation (ENI) groups. The composition ratio, prognostic factors and adverse events were analyzed between two groups. \u0000 \u0000 \u0000Results \u0000The median overall survival (OS) time was 35.5 months (95%CI : 30.12-40.88) and the median disease-free survival (DFS) time was 23.5 months (95%CI: 19.00-28.00). According to the multivariate analysis results, all patients were assigned into two groups at a ratio of 1 vs.1(n=86 in each group). Multivariate analysis after propensity score matching (PSM) demonstrated that irradiation method was the independent factor of OS (P=0.038), and T stage and radiotherapy were the independent factors affecting DFS (P=0.002, 0.032). The incidence of ≥grade Ⅱ adverse events did not significantly differ between two groups (P=0.819, 0.756). However, patients with combined chemotherapy experienced more adverse events. \u0000 \u0000 \u0000Conclusion \u0000ENI can prolong the OS and DFS of patients with clinical T2-3N0M0 esophageal squamous cell carcinoma, and does not increase the incidence of severe adverse events. \u0000 \u0000 \u0000Key words: \u0000Esophageal neoplasm/involved-field irradiation; Esophageal neoplasm/elective node irradiation; Prognosis","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"17-21"},"PeriodicalIF":0.0,"publicationDate":"2020-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42050012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-15DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.01.016
Liqing Zou, Yida Li, Xi Yang
Hyperthermia has been a research hot spot since it was approved by FDA as one of the 5 major therapeutic modalities for tumor since 1989. Pre-clinicaland clinical researches have confirmed the prominent radiosensitizing effect of hyperthermia. In this article, the research progress on hyperthermia combined with radiation therapy was summarized based upon clinical evidence. The challenges and issues during the procedure of hyperthermia combined with radiation therapy were analyzed from the perspectives of treatment temperature, frequency and interval time of hyperthermia, interval time and time sequence between hyperthermia and radiation therapy, etc. Besides, the application progress and prospect of hyperthermia combined with radiation therapy were reviewed, aiming to provide clinical evidence for the combination of hyperthermia and radiation therapy. Key words: Neoplasm/radiotherapy; Neoplasm/hyperthermia; Neoplasm/hyperthermia combined with radiation therapy; Research progress
{"title":"Progress on clinical research of hyperthermia combined with radiation therapy","authors":"Liqing Zou, Yida Li, Xi Yang","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.01.016","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.01.016","url":null,"abstract":"Hyperthermia has been a research hot spot since it was approved by FDA as one of the 5 major therapeutic modalities for tumor since 1989. Pre-clinicaland clinical researches have confirmed the prominent radiosensitizing effect of hyperthermia. In this article, the research progress on hyperthermia combined with radiation therapy was summarized based upon clinical evidence. The challenges and issues during the procedure of hyperthermia combined with radiation therapy were analyzed from the perspectives of treatment temperature, frequency and interval time of hyperthermia, interval time and time sequence between hyperthermia and radiation therapy, etc. Besides, the application progress and prospect of hyperthermia combined with radiation therapy were reviewed, aiming to provide clinical evidence for the combination of hyperthermia and radiation therapy. \u0000 \u0000 \u0000Key words: \u0000Neoplasm/radiotherapy; Neoplasm/hyperthermia; Neoplasm/hyperthermia combined with radiation therapy; Research progress","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"69-72"},"PeriodicalIF":0.0,"publicationDate":"2020-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46947586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-15DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.01.015
Xiangbin Zhang, Guangjun Li, Ying-jie Zhang
Dose-guided radiotherapy (DGRT) is a potentially useful adaptive radiotherapy method which dosimetrically compensates for interfractional non-rigid deformation. With the improvement of in-room imaging quality, development of the deformation registration algorithm and innovation of computer science, the wide application of DGRT might be realized. The purpose of this article is to briefly summarize the work flow, clinical application and prospect of DGRT. Key words: Dose-guided radiotherapy; Interfractional non-rigid deformation; Adaptive radiotherapy
{"title":"Clinical application and research progress on dose-guided radiotherapy","authors":"Xiangbin Zhang, Guangjun Li, Ying-jie Zhang","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.01.015","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.01.015","url":null,"abstract":"Dose-guided radiotherapy (DGRT) is a potentially useful adaptive radiotherapy method which dosimetrically compensates for interfractional non-rigid deformation. With the improvement of in-room imaging quality, development of the deformation registration algorithm and innovation of computer science, the wide application of DGRT might be realized. The purpose of this article is to briefly summarize the work flow, clinical application and prospect of DGRT. \u0000 \u0000 \u0000Key words: \u0000Dose-guided radiotherapy; Interfractional non-rigid deformation; Adaptive radiotherapy","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"65-68"},"PeriodicalIF":0.0,"publicationDate":"2020-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45463451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-15DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.01.002
Yi Xu, Ye Zhang, Shaoyan Liu, Xiaolei Wang, Xiao-dong Huang, Y. Qu, Kai Wang, R. Wu, Xue-song Chen, Qingfeng Liu, Shiran Sun, Xi Luo, Jingwei Luo, Li Gao, Guo-zhen Xu, J. Yi
Objective To investigate the pattern of lymph node metastasis (LNM) in patients with locally advanced (T3, T4) laryngeal squamous cell carcinoma (LALSC) and provide reference for the delineation of clinical target volume. Methods Clinical data of 272 patients with LALSC treated in our hospital from 2000 to 2017 were retrospectively analyzed. All patients underwent bilateral neck dissection (at least level Ⅱ-Ⅳ). The LNM ratio of each node level was calculated. The risk factors of LNM were identified by univariate and multivariate logistic regression analyses. Results LNM was found in 156 of 272 patients (57.1%). According to the location of primary lesions, all patients were divided into group A (n=72; unilateral without midline involvement), group B (n=86; unilateral with midline involvement) and group C (n=114; giant or central). In group A, the LNM ratio at ipsilateral level Ⅱ, Ⅲ and Ⅳ was 36.3%, 26.4% and 6.9%, whereas 13.9%, 8.3% and 1.4% at the contralateral level, respectively. In group B, the LNM ratio at ipsilateral level Ⅱ, Ⅲ and IV was 1.9%, 29.1% and 11.6%, whereas 18.6%, 14.0% and 1.2% at the contralateral level, respectively. In group C, the LNM ratio at the left neck level Ⅱ, Ⅲ and Ⅳ was 24.6%, 23.7% and 2.6%, whereas 21.9%, 26.3% and 6.1% at the right neck, respectively. Bilateral LNM ratio did not significantly differ between group A and group B/C (15.3%, 25.0%, P=0.093). Ipsilateral level Ⅲ metastasis (OR=2.929, 95%CI 1.041-8.245, P=0.042) and clinical N stage (OR=0.082, 95%CI 0.018-0.373, P=0.001) were associated with contralateral LNM. Ipsilateral level Ⅱ(P=0.043) or Ⅲ(P=0.009) metastasis were risk factors of the ipsilateral level Ⅳ metastasis. Conclusions Neck levels Ⅱ and Ⅲ are the high-risk LNM regions, whereaslevels Ⅳ and V are the low-risk areas. Ipsilateral level Ⅱ or Ⅲ metastases are the risk factors of ipsilateral level Ⅳ and contralateral cervical LNM. Contralateral neck LNM rarely occurs in cN0 stage patients. Key words: Locally advanced laryngeal cancer; Squamous cell carcinoma; Lymph node metastasis; Risk factor
{"title":"Patterns and risk factors of lymph node metastasis in locally advanced supraglottic squamous cell carcinoma","authors":"Yi Xu, Ye Zhang, Shaoyan Liu, Xiaolei Wang, Xiao-dong Huang, Y. Qu, Kai Wang, R. Wu, Xue-song Chen, Qingfeng Liu, Shiran Sun, Xi Luo, Jingwei Luo, Li Gao, Guo-zhen Xu, J. Yi","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.01.002","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.01.002","url":null,"abstract":"Objective \u0000To investigate the pattern of lymph node metastasis (LNM) in patients with locally advanced (T3, T4) laryngeal squamous cell carcinoma (LALSC) and provide reference for the delineation of clinical target volume. \u0000 \u0000 \u0000Methods \u0000Clinical data of 272 patients with LALSC treated in our hospital from 2000 to 2017 were retrospectively analyzed. All patients underwent bilateral neck dissection (at least level Ⅱ-Ⅳ). The LNM ratio of each node level was calculated. The risk factors of LNM were identified by univariate and multivariate logistic regression analyses. \u0000 \u0000 \u0000Results \u0000LNM was found in 156 of 272 patients (57.1%). According to the location of primary lesions, all patients were divided into group A (n=72; unilateral without midline involvement), group B (n=86; unilateral with midline involvement) and group C (n=114; giant or central). In group A, the LNM ratio at ipsilateral level Ⅱ, Ⅲ and Ⅳ was 36.3%, 26.4% and 6.9%, whereas 13.9%, 8.3% and 1.4% at the contralateral level, respectively. In group B, the LNM ratio at ipsilateral level Ⅱ, Ⅲ and IV was 1.9%, 29.1% and 11.6%, whereas 18.6%, 14.0% and 1.2% at the contralateral level, respectively. In group C, the LNM ratio at the left neck level Ⅱ, Ⅲ and Ⅳ was 24.6%, 23.7% and 2.6%, whereas 21.9%, 26.3% and 6.1% at the right neck, respectively. Bilateral LNM ratio did not significantly differ between group A and group B/C (15.3%, 25.0%, P=0.093). Ipsilateral level Ⅲ metastasis (OR=2.929, 95%CI 1.041-8.245, P=0.042) and clinical N stage (OR=0.082, 95%CI 0.018-0.373, P=0.001) were associated with contralateral LNM. Ipsilateral level Ⅱ(P=0.043) or Ⅲ(P=0.009) metastasis were risk factors of the ipsilateral level Ⅳ metastasis. \u0000 \u0000 \u0000Conclusions \u0000Neck levels Ⅱ and Ⅲ are the high-risk LNM regions, whereaslevels Ⅳ and V are the low-risk areas. Ipsilateral level Ⅱ or Ⅲ metastases are the risk factors of ipsilateral level Ⅳ and contralateral cervical LNM. Contralateral neck LNM rarely occurs in cN0 stage patients. \u0000 \u0000 \u0000Key words: \u0000Locally advanced laryngeal cancer; Squamous cell carcinoma; Lymph node metastasis; Risk factor","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"6-10"},"PeriodicalIF":0.0,"publicationDate":"2020-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44455109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-15DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.01.006
C. Fan, Zhu Feng, H. Ge, K. Ye, Hao Wang, Xiao-li Zheng, Yougai Zhang
Objective To evaluate the clinical efficacy and prognostic factors of recurrent esophageal squamous cell carcinoma after neoadjuvant therapy combined with surgery. Methods From December 2011 to December 2015, 152 cases of recurrent thoracic esophageal squamous cell carcinoma after neoadjuvant therapy combined with surgery were retrospectively analyzed. The overall survival (OS) after treatment failure, clinical efficacy and prognostic factors of different salvage treatments were analyzed. OS was calculated by Kaplan-Meier method. Prognostic analysis was performed by using multivariate Cox regression model. Results The median interval of the first recurrence was 10.6(2.0 to 69.1) months. The median OS after recurrence was 8.0(0.8 to 43.3) months. The 1-, 2-and 3-year OS rates after recurrence were 36.0%, 15.1% and 5.2%, respectively. The median OS of patients with locoregional recurrence alone, distant metastasis alone and locoregional recurrence combined with distant metastasis was 11.3(1.8 to 43.3) months, 6.7(1.2 to 28.6) months and 5.1(0.8 to 22.9) months, respectively. Multivariate analysis demonstrated that neoadjuvant chemotherapy (P=0.009), ypTNM stage (P=0.012), comprehensive treatment after recurrence (P=0.000) and locoregional recurrence (P=0.026) were independently correlated with the OS of patients with recurrent esophageal squamous cell carcinoma. Conclusions Neoadjuvant therapy, ypTNM stage, recurrence pattern and post-recurrence treatment are the independent risk factors for clinical prognosis of patients with recurrent esophageal squamous cell carcinoma after neoadjuvant therapy combined with surgery. Clinical prognosis of patients with recurrent esophageal squamous cell carcinoma after neoadjuvant therapy is not satisfactory. After recurrence, combined treatment mode should be adopted according to the site of recurrence and neoadjuvant treatment mode to maximize the benefits of salvage treatment. Key words: Esophageal neoplasm, recurrent/ neoadjuvant treatment; Locoregional recurrence; Distant metastasis; Prognosis
{"title":"Prognostic analysis of recurrent esophageal squamous cell carcinoma after neoadjuvant therapy combined with surgical treatment","authors":"C. Fan, Zhu Feng, H. Ge, K. Ye, Hao Wang, Xiao-li Zheng, Yougai Zhang","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.01.006","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.01.006","url":null,"abstract":"Objective \u0000To evaluate the clinical efficacy and prognostic factors of recurrent esophageal squamous cell carcinoma after neoadjuvant therapy combined with surgery. \u0000 \u0000 \u0000Methods \u0000From December 2011 to December 2015, 152 cases of recurrent thoracic esophageal squamous cell carcinoma after neoadjuvant therapy combined with surgery were retrospectively analyzed. The overall survival (OS) after treatment failure, clinical efficacy and prognostic factors of different salvage treatments were analyzed. OS was calculated by Kaplan-Meier method. Prognostic analysis was performed by using multivariate Cox regression model. \u0000 \u0000 \u0000Results \u0000The median interval of the first recurrence was 10.6(2.0 to 69.1) months. The median OS after recurrence was 8.0(0.8 to 43.3) months. The 1-, 2-and 3-year OS rates after recurrence were 36.0%, 15.1% and 5.2%, respectively. The median OS of patients with locoregional recurrence alone, distant metastasis alone and locoregional recurrence combined with distant metastasis was 11.3(1.8 to 43.3) months, 6.7(1.2 to 28.6) months and 5.1(0.8 to 22.9) months, respectively. Multivariate analysis demonstrated that neoadjuvant chemotherapy (P=0.009), ypTNM stage (P=0.012), comprehensive treatment after recurrence (P=0.000) and locoregional recurrence (P=0.026) were independently correlated with the OS of patients with recurrent esophageal squamous cell carcinoma. \u0000 \u0000 \u0000Conclusions \u0000Neoadjuvant therapy, ypTNM stage, recurrence pattern and post-recurrence treatment are the independent risk factors for clinical prognosis of patients with recurrent esophageal squamous cell carcinoma after neoadjuvant therapy combined with surgery. Clinical prognosis of patients with recurrent esophageal squamous cell carcinoma after neoadjuvant therapy is not satisfactory. After recurrence, combined treatment mode should be adopted according to the site of recurrence and neoadjuvant treatment mode to maximize the benefits of salvage treatment. \u0000 \u0000 \u0000Key words: \u0000Esophageal neoplasm, recurrent/ neoadjuvant treatment; Locoregional recurrence; Distant metastasis; Prognosis","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"26-30"},"PeriodicalIF":0.0,"publicationDate":"2020-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41748371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：